Category: Latest News

  • Perma-Fix secures Hanford waste subcontract under $4.37 billion programme

    Perma-Fix secures Hanford waste subcontract under $4.37 billion programme

    Perma-Fix Environmental Services (NASDAQ:PESI) has secured a Master Indefinite Delivery/Indefinite Quantity subcontract from Hanford Tank Waste Operations & Closure, LLC (H2C) covering the treatment and disposal of pretreated liquid mixed low-level waste from the U.S. Department of Energy’s Hanford Site in southeastern Washington State. The subcontract became effective on August 11, 2026, and allows H2C…

  • Milestone Pharmaceuticals shares tumble after Q2 earnings miss

    Milestone Pharmaceuticals shares tumble after Q2 earnings miss

    Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares dropped 12.60% on Wednesday after the biopharmaceutical company reported a second-quarter loss that was wider than Wall Street expected, despite continued progress with the commercial launch of CARDAMYST. For the quarter ended June 30, 2026, Milestone recorded an adjusted loss of $0.21 per share, compared with the analyst consensus forecast…

  • Brinker International shares dip after earnings miss despite strong 2027 guidance

    Brinker International shares dip after earnings miss despite strong 2027 guidance

    Brinker International, Inc. (NYSE:EAT) shares fell 1.98% in premarket trading after the parent company of Chili’s Grill & Bar and Maggiano’s Little Italy reported fiscal fourth-quarter earnings slightly below Wall Street expectations, although its outlook for fiscal 2027 came in well ahead of forecasts. Adjusted earnings per share reached $3.07 for the quarter ended June…

  • Definium Therapeutics shares surge after positive Phase 3 anxiety trial results

    Definium Therapeutics shares surge after positive Phase 3 anxiety trial results

    Definium Therapeutics (NASDAQ:DFTX) shares jumped 20% in premarket trading on Wednesday after the company announced positive topline results from its Phase 3 Voyage study evaluating DT120 ODT in patients with generalised anxiety disorder. The trial achieved its primary endpoint as well as all key secondary efficacy endpoints, providing another positive late-stage clinical result for the…

  • Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

    Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

    Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares gained 2.00% in premarket trading on Wednesday after the clinical-stage biotechnology company reported a second-quarter loss that was considerably narrower than Wall Street expected. The company posted a loss of $0.06 per share for the quarter, compared with the analyst consensus forecast for a loss of $0.48 per share. Unicycive,…

  • Local Bounti shares fall after second-quarter revenue misses forecasts

    Local Bounti shares fall after second-quarter revenue misses forecasts

    Local Bounti Corporation (NYSE:LOCL) shares fell 4.76% in premarket trading after the indoor agriculture company reported second-quarter revenue and adjusted earnings below Wall Street expectations, despite delivering year-on-year sales growth and reducing its losses. Revenue reached $13.9 million, well below the analyst consensus estimate of $22 million. The company reported an adjusted loss of $0.68…

  • Madison Square Garden Entertainment shares rise after Q4 results beat forecasts

    Madison Square Garden Entertainment shares rise after Q4 results beat forecasts

    Madison Square Garden Entertainment Corp. (NYSE:MSGE) shares gained 3.31% in premarket trading on Wednesday after the live entertainment company reported fiscal fourth-quarter earnings and revenue above Wall Street expectations. The company posted a quarterly loss of $0.21 per share, considerably narrower than the analyst consensus forecast for a loss of $0.58 per share. Revenue climbed…

  • Annexon shares fall as second-quarter loss exceeds Wall Street forecasts

    Annexon shares fall as second-quarter loss exceeds Wall Street forecasts

    Annexon, Inc. (NASDAQ:ANNX) shares declined 6.37% in premarket trading on Wednesday after the biopharmaceutical company reported a wider-than-expected second-quarter loss as spending increased across its late-stage clinical programmes. For the quarter ended June 30, Annexon recorded a loss of $0.28 per share, compared with the Wall Street consensus estimate for a loss of $0.24 per…

  • BETA Technologies shares fall after wider-than-expected second-quarter loss

    BETA Technologies shares fall after wider-than-expected second-quarter loss

    BETA Technologies, Inc. (NYSE:BETA) shares fell 4.47% in premarket trading on Wednesday after the aerospace and defence company reported a second-quarter loss that was wider than Wall Street had anticipated. For the quarter ended June 30, 2026, BETA posted an adjusted loss of $0.64 per share, compared with the analyst consensus for a loss of…

  • Boyd Group Services misses Q2 forecasts despite strong revenue and EBITDA growth

    Boyd Group Services misses Q2 forecasts despite strong revenue and EBITDA growth

    Boyd Group Services Inc. (NYSE:BGSI) reported second-quarter earnings and revenue below Wall Street expectations on Wednesday, despite delivering substantial year-on-year growth and surpassing $1 billion in quarterly revenue for the first time. Adjusted earnings per share came in at $0.80, missing the consensus estimate of $0.99 by $0.19. Revenue reached $1.01 billion, below the $1.03…